Amgen was buoyed by the news that new data demonstrates that motesanib slowed the progression of metastatic thyroid cancer. Out of 93 patients in the study, 49 had a positive response. Volunteers with a BRAF V600E mutation did better than those without the mutation. Report [1]
Links:
[1] http://www.washingtonpost.com/wp-dyn/content/article/2008/07/02/AR2008070202579.html